Revising Pediatric Vancomycin Dosing Accounting for Nephrotoxicity in a Pharmacokinetic-Pharmacodynamic Model-Reference-Cited by-同舟云学术

Revising Pediatric Vancomycin Dosing Accounting for Nephrotoxicity in a Pharmacokinetic-Pharmacodynamic Model

Published:2019-05 Issue:5 Volume:63 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Kloprogge Frank¹^ORCID,Hill Louise F.²³,Booth John⁴,Klein Nigel²⁴,Irwin Adam D.²⁴⁵,Dixon Garth²⁴,Standing Joseph F.²⁴

Affiliation:

1. Institute for Global Health, University College London, London, United Kingdom

2. Great Ormond Street Institute of Child Health, University College London, London, United Kingdom

3. Institute for Infection and Immunity, St. George’s, University of London, London, United Kingdom

4. Great Ormond Street Hospital, London, United Kingdom

5. The University of Queensland Centre for Clinical Research, Herston, Queensland, Australia

Abstract

This study aimed to suggest an initial pediatric vancomycin dose regimen through population pharmacokinetic-pharmacodynamic modeling. A population pharmacokinetic approach was used to analyze vancomycin concentration-time data from a large pediatric cohort.

Funder

RCUK | Medical Research Council

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.00067-19

Reference39 articles.

1. BNF. 2018. BNF for children 2018-2019. BMJ Group, London, United Kingdom.

2. Vancomycin pharmacokinetics in preterm neonates and the prediction of adult clearance

3. Pediatric Patients With Solid or Hematological Tumor Disease: Vancomycin Population Pharmacokinetics and Dosage Optimization